ArticleScience (New York, N.Y.)2020
Interferon responses in viral pneumonias.
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Antiviral treatment for viral pneumonia: current drugs and natural compounds.Virology journal · 2025Review
- Article
- Oxidative stress in patients with coronavirus disease and end-stage renal disease: a pilot study.BMC nephrology · 2024Article
- The Src-ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage.The Journal of experimental medicine · 2023Article
- More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients.Frontiers in immunology · 2023Article
- Review
- Favorable Genotypes of Type III Interferon Confer Risk of Dyslipidemia in the Population With Obesity.Frontiers in endocrinology · 2022Article
- Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes.Environmental microbiology · 2021Review
- SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.Journal of medical virology · 2021Article
- Dissecting the common and compartment-specific features of COVID-19 severity in the lung and periphery with single-cell resolution.iScience · 2021Article
- Article
- Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.International immunopharmacology · 2021Article
- Does Covera-19 know 'when to hold 'em or 'when to fold 'em? A translational thought experiment.Translational medicine communications · 2021Review
- Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1.Frontiers in immunology · 2021Article
- Review
- Cytokine Storm.The New England journal of medicine · 2020Review
- Update on animal models for COVID-19 research.British journal of pharmacology · 2020Article
- The Role of Structure in the Biology of Interferon Signaling.Frontiers in immunology · 2020Review
- When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak.Frontiers in immunologyReview
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.